Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.600
+0.060 (1.32%)
Aug 6, 2026, 10:30 AM EDT - Market open
Prelude Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 21.76 | 35.26 | 12.47 | 25.29 | 30.61 | 31.83 |
Short-Term Investments | 59.8 | 67.96 | 121.14 | 207.64 | 171.12 | 259.41 |
Cash & Short-Term Investments | 81.55 | 103.21 | 133.61 | 232.94 | 201.73 | 291.23 |
Cash Growth | -17.68% | -22.75% | -42.64% | 15.47% | -30.73% | 33.40% |
Other Current Assets | 3.04 | 2.48 | 2.28 | 2.65 | 2.65 | 3.88 |
Total Current Assets | 84.59 | 105.69 | 135.9 | 235.59 | 204.38 | 295.12 |
Net Property, Plant & Equipment | 31.5 | 32.28 | 35.47 | 37.74 | 6.7 | 5.64 |
Other Long-Term Assets | 3.55 | 3.35 | 4.15 | 4.34 | 9.42 | 4.35 |
Total Assets | 119.64 | 141.32 | 175.52 | 277.67 | 220.5 | 305.1 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.07 | 3.98 | 7.73 | 4.58 | 6.78 | 7.84 |
Accrued Expenses | 5.94 | 12.53 | 15.21 | 15.77 | 13.09 | 9.62 |
Current Portion of Leases | 2.76 | 2.74 | 2.7 | 1.48 | 1.83 | 1.74 |
Unearned Revenue | 30.95 | 33.73 | - | - | - | - |
Total Current Liabilities | 41.72 | 52.99 | 25.64 | 21.83 | 21.7 | 19.2 |
Long-Term Leases | 14.96 | 15.05 | 15.33 | 18.75 | - | - |
Other Long-Term Liabilities | 2.78 | 4.64 | 3.09 | - | 3.36 | - |
Total Long-Term Liabilities | 17.74 | 19.68 | 18.42 | 18.75 | 3.36 | - |
Total Liabilities | 59.46 | 72.68 | 44.06 | 40.58 | 25.06 | 19.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 753.66 | 751.68 | 714.98 | 693.25 | 531.68 | 505.72 |
Accumulated Other Comprehensive Income | -0.04 | 0.01 | 0.04 | 0.22 | -1.69 | -0.71 |
Retained Earnings | -693.45 | -683.06 | -583.56 | -456.39 | -334.56 | -219.12 |
Shareholders' Equity | 60.18 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Total Liabilities & Equity | 119.64 | 141.32 | 175.52 | 277.67 | 220.5 | 305.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 17.72 | 17.79 | 18.03 | 20.23 | 1.83 | 1.74 |
Net Cash (Debt) | 63.83 | 85.43 | 115.59 | 212.71 | 199.9 | 289.49 |
Net Cash Growth | -21.34% | -26.10% | -45.66% | 6.41% | -30.95% | 32.61% |
Net Cash Per Share | 0.81 | 1.11 | 1.52 | 3.52 | 4.22 | 6.29 |
Book Value | 60.18 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Book Value Per Share | 0.77 | 0.89 | 1.73 | 3.93 | 4.13 | 6.21 |
Tangible Book Value | 60.18 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Tangible Book Value Per Share | 0.77 | 0.89 | 1.73 | 3.93 | 4.13 | 6.21 |